Free Trial
NASDAQ:ACON

Aclarion Q2 2025 Earnings Report

Aclarion logo
$7.48 +0.04 (+0.47%)
Closing price 09/12/2025 03:58 PM Eastern
Extended Trading
$7.64 +0.15 (+2.00%)
As of 09/12/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclarion EPS Results

Actual EPS
-$2.75
Consensus EPS
-$2.26
Beat/Miss
Missed by -$0.49
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.03 million
Beat/Miss
Missed by -$10.00 thousand
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Aclarion's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Friday, November 14, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Aclarion Earnings Headlines

Aclarion taps Greg Gould as CFO
Aclarion, Inc. Appoints Greg Gould as CFO
Alert: Prepare for Trump's Dollar Overhaul
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
Aclarion Appoints Greg Gould as Chief Financial Officer
Aclarion, Inc. (ACON) - Yahoo Finance
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile

More Earnings Resources from MarketBeat